TY - JOUR
T1 - Dose-Dependent Pharmacokinetics of Carbamazepine in Rats
T2 - Determination of the Formation Clearance of Carbamazepine-10,11-epoxide
AU - Remmel, Rory P
AU - Sinz, Michael W.
AU - Cloyd, James C
PY - 1990/5
Y1 - 1990/5
N2 - The dose dependency of carbamazepine pharmacokinetics was characterized in rats, a common test animal for antiepileptic drug efficacy. With a randomized Latin square schedule, 5, 10, and 20 mg/kg doses of carbamazepine were injected intravenously into six Sprague-Dawley rats followed by the administration of a 5 or 10 mg/kg i.v. dose of CBZ-E to each rat. Following administration, the concentrations of CBZ and Carbamazepine-10,11-epoxide (CBZ-E) in whole blood were determined by a reverse-phase HPLC assay. Plasma protein binding of both carbamazepine and CBZ-E was linear over the concentration range observed in this study. Carbamazepine concentration–time plots were log-linear, but the slopes were not parallel. Carbamazepine total-body clearances were 15.1 ± 3.26, 13.4 ± 5.66, and 10.0 ± 3.11 ml/min/kg at the 5, 10, and 20 mg/kg doses, respectively (significance of difference between the 5 and the 20 mg/kg dose = 0.06 < P < 0.05; Kruskal–Wallis test, Dunn's procedure). However, the formation clearance to CBZ-E did not change, suggesting that metabolism via other pathways was decreased at higher carbamazepine doses.
AB - The dose dependency of carbamazepine pharmacokinetics was characterized in rats, a common test animal for antiepileptic drug efficacy. With a randomized Latin square schedule, 5, 10, and 20 mg/kg doses of carbamazepine were injected intravenously into six Sprague-Dawley rats followed by the administration of a 5 or 10 mg/kg i.v. dose of CBZ-E to each rat. Following administration, the concentrations of CBZ and Carbamazepine-10,11-epoxide (CBZ-E) in whole blood were determined by a reverse-phase HPLC assay. Plasma protein binding of both carbamazepine and CBZ-E was linear over the concentration range observed in this study. Carbamazepine concentration–time plots were log-linear, but the slopes were not parallel. Carbamazepine total-body clearances were 15.1 ± 3.26, 13.4 ± 5.66, and 10.0 ± 3.11 ml/min/kg at the 5, 10, and 20 mg/kg doses, respectively (significance of difference between the 5 and the 20 mg/kg dose = 0.06 < P < 0.05; Kruskal–Wallis test, Dunn's procedure). However, the formation clearance to CBZ-E did not change, suggesting that metabolism via other pathways was decreased at higher carbamazepine doses.
KW - blood
KW - carbamazepine
KW - carbamazepine-10,11-epoxide
KW - dose dependency
KW - metabolite
KW - pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=0025025808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025025808&partnerID=8YFLogxK
U2 - 10.1023/A:1015872901523
DO - 10.1023/A:1015872901523
M3 - Article
C2 - 2367320
AN - SCOPUS:0025025808
SN - 0724-8741
VL - 7
SP - 513
EP - 517
JO - Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists
JF - Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists
IS - 5
ER -